These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: The role of transforming growth factor beta in Dupuytren's disease.
    Author: Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K.
    Journal: J Hand Surg Am; 1996 Mar; 21(2):210-5. PubMed ID: 8683048.
    Abstract:
    This study was undertaken to mark immunologically intracellular and extracellular sites of two common transforming growth factor beta (TGF-beta) isoforms, TGF-beta1 and TGF-beta2, in the proliferative, involutional, and residual stages of Dupuytren's disease. The effect of TGF-beta on myofibroblast proliferation was also studied using explant cultures from Dupuytren's nodules in the proliferative or involutional stage. TGF-beta1, TGF-beta2 and the combination of both isoforms were studied at low and high myofibroblast plating densities to simulate respectively proliferative or involutional disease stage conditions. Our results indicate that TGF-beta1 showed an intense intracellular marking pattern associated with fibroblasts, myofibroblasts, and capillary endothelial cells in all Dupuytren's samples, regardless of disease stage. TGF-beta2 showed an intense intracellular localization within myofibroblasts in the proliferative and involutional stages. Fibroblasts in the residual stage did not contain TGF-beta2. Neither isoform was present in the extracellular matrix. Results of cell culture indicate that compared with control myofibroblasts, the addition of TGF-beta1, TGF-beta2 and TGF-beta1 + beta2 had significant effects on myofibroblast proliferation, especially at higher plating densities. However, TGF-beta2 had the most significant proliferative effect.
    [Abstract] [Full Text] [Related] [New Search]